Welcome to our dedicated page for Erasca SEC filings (Ticker: ERAS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Erasca, Inc. filings document a clinical-stage oncology issuer focused on RAS/MAPK pathway-driven cancers and common stock listed on the Nasdaq Global Select Market. Recent Form 8-K reports disclose ERAS-0015 clinical data from AURORAS-1 and JYP0015M101, Regulation FD materials, financial results, cash and marketable-securities information, and common-stock offering activity under a shelf registration statement.
Proxy materials cover annual meeting procedures, director elections, executive compensation, and stockholder voting matters. Other event reports record intellectual-property correspondence involving ERAS-0015 and provide formal updates on the company's pipeline, capital structure, and public-company governance.
Erasca, Inc. updated the expected timing for initial Phase 1 monotherapy data from its pan-RAS molecular glue ERAS-0015, now guiding that data from the AURORAS-1 and JYP0015M101 trials will be available no later than mid-May 2026, compared with its prior expectation of the first half of 2026.
AURORAS-1 is evaluating ERAS-0015 in patients with RAS-mutant solid tumors, while licensor Guangzhou Joyo Pharmatech Co., Ltd. is running JYP0015M101 in China in patients with advanced solid tumors harboring specific RAS mutations. The company also highlights typical forward-looking statement risks and directs readers to its risk factor disclosures.
Erasca Foundation reported proposed sales of Common stock in Form 144/A. The filing lists sales dated 01/15/2026, 02/17/2026, and 03/16/2026 with amounts $68,573.87, $99,245.03, and $116,855.46 respectively. The entries are recorded under Erasca Foundation's address in San Diego and identify the securities as Common stock.
Erasca Foundation reported sale transactions of Common stock via Form 144 and lists multiple recent dispositions by the foundation. The filing itemizes dated transfers on 01/15/2026, 02/17/2026, and 03/16/2026 with corresponding amounts shown in the excerpt.
Erasca, Inc. Chief Legal Officer Ebun Garner exercised stock options and sold shares in a planned transaction. On April 1, 2026, Garner exercised options to acquire 80,000 shares of common stock at $1.70 per share, converting a derivative position into common stock.
That same day, Garner sold 80,000 shares of common stock at a weighted-average price of $16.40 per share in open-market transactions, executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 30, 2024. Following these transactions, Garner directly held 25,076 shares of Erasca common stock.
Erasca, Inc. filed a Form 144 reporting a proposed sale of 80,000 shares of Common Stock associated with a stock option, planned for 04/01/2026 and to be settled for cash. The filing shows an aggregate value of $1,312,354.68 and lists 310,799,547 shares outstanding as of 04/01/2026 as a context figure. The filer also reported a prior sale of 120,000 shares on 01/07/2026 for $670,809.15.
Erasca, Inc. Form 144 filing notifies proposed sales of Common stock by the Erasca Foundation as reported on the form. The filing lists multiple entries with a recurring figure 8333 associated with each sale line and transaction dates such as 02/17/2026, 01/15/2026, and 12/15/2025.
Examples shown include Erasca Foundation entries dated 02/17/2026 (8333) and 01/15/2026 (8333). The filing identifies Nasdaq as the market and includes an apparent reporting date of 03/16/2026.
Erasca, Inc. files its annual report describing a focused strategy to develop precision oncology drugs that shut down the RAS/MAPK pathway in cancer. The company highlights two clinical-stage programs, ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS inhibitor), plus discovery-stage EGFR antibody ERAS-12.
Early Phase 1 data for ERAS-0015 show partial responses at low doses with favorable safety and linear pharmacokinetics. Erasca exercised its option to expand territorial rights for ERAS-0015 globally (including mainland China) under its Joyo license and is preparing multiple monotherapy and combination readouts in 2026–2027.
The company streamlined its portfolio by terminating several legacy programs and license agreements to concentrate resources on its RAS franchise and EGFR antibody platform. As of June 30, 2025, non-affiliate common stock held an aggregate market value of $316.4 million, and common shares outstanding totaled 310,799,547 as of March 5, 2026.
Erasca, Inc. reported fourth quarter and full year 2025 results alongside business and pipeline updates. For 2025, net loss narrowed to $124.5 million, or $(0.44) per share, from $161.7 million, or $(0.69) per share, in 2024 as operating expenses declined.
Research and development expenses fell to $92.9 million from $115.4 million, while general and administrative expenses decreased to $38.6 million from $41.7 million. Cash, cash equivalents, and marketable securities were $341.8 million as of December 31, 2025, down from $440.5 million a year earlier.
The company completed an upsized public offering in January 2026, raising approximately $258.8 million in gross proceeds and expects pro forma cash of $434 million to fund operations into the second half of 2028. Erasca highlighted encouraging early clinical activity for ERAS-0015, continued advancement of ERAS-4001, and new U.S. composition-of-matter patents supporting its RAS-targeting franchise, with multiple Phase 1 data readouts and trial expansions planned in 2026 and 2027.
Erasca, Inc. Chief Medical Officer Morris Shannon reported an option exercise and related share sale. On March 4, 2026, he exercised options for 20,000 shares of common stock at $1.70 per share and sold 20,000 shares in open-market transactions at a weighted-average price of $15.038 per share. These transactions were carried out under a previously adopted Rule 10b5-1 trading plan. Following a related derivative entry dated March 4, 2025, he held 515,800 stock options, which vest monthly in 48 installments starting February 1, 2024, contingent on continued service.